Why are patients with chronic myeloid leukaemia (non-)adherent

British Journal of Cancer

Volumn 107, Issue 6, 2012, Pages 901-903

  Abraham, I ^a,b   MacDonald, K ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b Matrix45   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

BEHAVIOR; CANCER CHEMOTHERAPY; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; COMORBIDITY; DOCTOR NURSE RELATION; DOCTOR PATIENT RELATION; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HEALTH CARE PERSONNEL; HUMAN; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PHARMACIST; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; SOCIAL SUPPORT; STRUCTURED INTERVIEW; TREATMENT RESPONSE;

EID: 84865857911     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.349     Document Type: Editorial

References (17)

1. Deininger M, O'Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP, Radich JP, Hatfield AK, Mone M, Filian J, Reynolds J, Gathmann I, Larson RA, Druker BJ (2009) International randomized study of interferon vs. STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression of events in patients with newly diagnoses chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 114(22): 1126 (abstract)
2. De Geest S, Abraham I, Moons P, Vandeputte M, Van Cleemput J, Evers G, Danene W, Vanhaecke J (1998) Late acute rejections and subclinical noncompliance with cyclosporine therapy in heart transplant patients. J Heart Lung Transplant 17: 854-863
3. DiMatteo MR (2004a) Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 42(3): 200-209
4. DiMatteo MR (2004b) Social support and patient adherence to medical treatment: a meta-analysis. Health Psychol 23(2): 207-218
5. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MWN, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Bl Powell, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepher J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA, for the IRIS Investigators (2006) Five-year followup of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355(23): 2408-2417
6. Efficace F, Baccarani M, Rosti G, Cottone F, Castagnetti F, Breccia M, Alimena G, Iurlo A, Rossi AR, Pardini S, Gherlinzoni F, Salvucci M, Tiribelli M, Vignetti M, Mandelli F (2012) Investigating factors associated with adherence behavior in patients with chronic myeloid leukemia: an observational patient-centered outcome study. Br J Cancer 107: 904-909
7. Eliasson L, Clifford S, Barber N, Marin D (2011) Exploring chronic myeloid leukemia patients' reason for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res 35(5): 626-630
8. Gambacorti-Passerini C, Antolini L, Mahon FX, Guilhot F, Deininger M, Fava C, Nagler A, Della Casa CM, Morra E, Abruzzese E, D'Emilio A, Stagna F, le Coutre P, Hurtado-Monroy R, Santini V, Martino B, Pane F, Piccin A, Giraldo P, Assouline S, Durosinmi MA, Leeksma O, Pogliani EM, Puttini M, Jan E, Reiffers J, Valsecchi MG, Kim DW (2011) Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Nat Cancer Inst 103(7): 553-561
9. Ganesan P, Sagar TG, Dubashi B, Rajendranath R, Kannan K, Cyriac S, Nandennavar M (2011) Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. Am J Hematol 86(6): 471-474
10. Hochhaus A, Druker B, Sawyers C, Guilhot F, Schiffer CA, Cortes J, Niederwieser DW, Gambacorti-Passerini C, Stone RM, Goldman J, Fischer T, O'Brien SG, Reiffers JJ, Mone M, Krahnke T, Talpaz M, Kantarjian HM (2008) Favorable long-term follow-up results after 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-a treatment. Blood 111(3): 1039-1043
11. Ibrahim AR, Eliasson L, Apperley JF, Milojkovic D, Bua M, Szydlo R, Mahon FX, Kozlowski K, Paliompeis C, Foroni L, Khorashad JS, Bazeos A, Molimard M, Reid A, Rezvani K, Gerrard G, Goldman J, Marin D (2011) Poor adherence is the main the reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 117(14): 3733-3736
12. Jönsson S, Olsson B, Söderberg J, Wadenvik H (2012) Good adherence to imatinib therapy among patients with chronic myeloid leukemia-a single center observational study. Ann Hematol 91(5): 679-685
13. Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, Apperley JF, Szydlo R, Desai R, Kozlowski K, Paliompeis C, Latham V, Foroni L, Molimard M, Reid A, Rezvani K, de Lavallade H, Guallar C, Goldman J, Khorashad JS (2010) Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 28(14): 2381-2388
14. Noens L, van Lierde MA, De Bock R, Verhoef G, Zachée P, Berneman Z, Martiat P, Mineur P, Van Eygen K, MacDonald K, De Geest S, Albrecht T, Abraham I (2009) Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 113(22): 5401-5411
15. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepher J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ, For the IRIS Investigators (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348(11): 994-1004
16. Partridge AH, Avorn J, Wang PS, Winer EP (2002) Adherence to therapy with oral antineoplastic agents. J Nat Cancer Inst 94(9): 652-661
17. Ruddy K, Mayer E, Partridge A (2009) Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 59(1): 56-66